Parsippany, NJ – According to filings with the U.S. Securities and Exchange Commission, Pyros Pharmaceuticals is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Smith played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Pyros Pharmaceuticals

Pyros Pharmaceuticals is an emerging generic drug company dedicated to developing and commercializing low-cost generics in the United States. Research and development is the cornerstone of our growth strategy. Providing quality products through scientific innovations, diligence and precision is the goal of all of Pyros research programs. Pyros develops high-quality, proprietary and off-patent pharmaceuticals for the US market. Our business strategy is focused on targeting high-value solid oral, sterile injectable and alternative dosage form ANDAs that are difficult to develop and that bring sustainable profitability. We explore a broad range of therapeutic areas that have technically challenging drug delivery mechanisms or other niches, including products with the potential for six months of exclusivity for being first-to-file or first-to-market. Our goal is to create a broad portfolio of limited source branded and generic pharmaceutical products that will provide high-quality, affordable and accessible alternatives.

To learn more about Pyros Pharmaceuticals, visit http://pyrospharma.com/

Contact:
Michael Smith, Chief Executive Officer
201-743-9468
msmith@pyrospharma.com
https://www.linkedin.com/in/michael-smith-84981450/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved